A Q and A on the Findings of the HOPE Trial

Special commentaries by:
Pierre Larochelle¹,
Ellen P. Burgess²,
Ernesto L. Schiffrin³,
Simon Kouz⁴, and
Michael Adams⁵

¹Assistant Director, Clinical Research Centre,
Centre Hospitalier de l'Université de Montréal-Campus Hôtel-Dieu,
Professor of Pharmacology,
Université de Montréal, Montreal, Quebec.

²Active Staff & Director, Foothills Medical Centre,
Associate Professor of Medicine,
University of Calgary, Calgary, Alberta.

³Director, Multidisciplinary Hypertension Group,
Hypertension & Lipid Clinic and Clinical Research Institute of Montreal, and
Professor of Medicine, Université de Montréal, Montreal, Quebec.

⁴Chief, Cardiology Service & Director,
Clinical Research Unit in Cardiology,
Centre Hospitalier Régional de Lanaudière, Joliette, Quebec.

⁵Head, Department of Pharmacology and Toxicology,
Queen's University, Kingston, Ontario.

Did the Results of the HOPE Trial Come as a Surprise?
Dr. Ernesto L. Schiffrin. Not at all. Our research group has been conducting numerous studies on ACE inhibitors for a number of years.